{"id":55729,"date":"2023-04-12T13:06:33","date_gmt":"2023-04-12T11:06:33","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/glaukos-to-release-first-quarter-2023-financial-results-after-market-close-on-may-3\/"},"modified":"2023-04-12T13:06:33","modified_gmt":"2023-04-12T11:06:33","slug":"glaukos-to-release-first-quarter-2023-financial-results-after-market-close-on-may-3","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/glaukos-to-release-first-quarter-2023-financial-results-after-market-close-on-may-3\/","title":{"rendered":"Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3"},"content":{"rendered":"
\n

\nConference Call and Webcast Scheduled for 1:30 p.m. PT<\/i><\/p>\n

ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2023 financial results after the market close on Wednesday, May 3, 2023. The company\u2019s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on May 3, 2023.<\/p>\n

\nA link to the live webcast will be available on the company\u2019s website at http:\/\/investors.glaukos.com<\/a>. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742. A replay will be archived on the company\u2019s website following completion of the call.<\/p>\n

\nAbout Glaukos<\/b><\/p>\n

\nGlaukos (www.glaukos.com<\/a>) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.<\/p>\n

Contacts<\/b> <\/p>\n

\nChris Lewis
\n
Vice President, Investor Relations and Corporate Affairs
\n
(949) 481-0510
\n
clewis@glaukos.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2023 financial results after the market close on Wednesday, May 3, 2023. The … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55729","6":"format-standard","7":"category-industry"},"yoast_head":"\nGlaukos to Release First Quarter 2023 Financial Results after Market Close on May 3 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/glaukos-to-release-first-quarter-2023-financial-results-after-market-close-on-may-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2023 financial results after the market close on Wednesday, May 3, 2023. The ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/glaukos-to-release-first-quarter-2023-financial-results-after-market-close-on-may-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-12T11:06:33+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glaukos-to-release-first-quarter-2023-financial-results-after-market-close-on-may-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glaukos-to-release-first-quarter-2023-financial-results-after-market-close-on-may-3\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3\",\"datePublished\":\"2023-04-12T11:06:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glaukos-to-release-first-quarter-2023-financial-results-after-market-close-on-may-3\\\/\"},\"wordCount\":263,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glaukos-to-release-first-quarter-2023-financial-results-after-market-close-on-may-3\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glaukos-to-release-first-quarter-2023-financial-results-after-market-close-on-may-3\\\/\",\"name\":\"Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-04-12T11:06:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glaukos-to-release-first-quarter-2023-financial-results-after-market-close-on-may-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glaukos-to-release-first-quarter-2023-financial-results-after-market-close-on-may-3\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glaukos-to-release-first-quarter-2023-financial-results-after-market-close-on-may-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/glaukos-to-release-first-quarter-2023-financial-results-after-market-close-on-may-3\/","og_locale":"en_US","og_type":"article","og_title":"Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3 - Pharma Trend","og_description":"Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2023 financial results after the market close on Wednesday, May 3, 2023. The ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/glaukos-to-release-first-quarter-2023-financial-results-after-market-close-on-may-3\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-12T11:06:33+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/glaukos-to-release-first-quarter-2023-financial-results-after-market-close-on-may-3\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/glaukos-to-release-first-quarter-2023-financial-results-after-market-close-on-may-3\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3","datePublished":"2023-04-12T11:06:33+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/glaukos-to-release-first-quarter-2023-financial-results-after-market-close-on-may-3\/"},"wordCount":263,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/glaukos-to-release-first-quarter-2023-financial-results-after-market-close-on-may-3\/","url":"https:\/\/pharma-trend.com\/en\/glaukos-to-release-first-quarter-2023-financial-results-after-market-close-on-may-3\/","name":"Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-04-12T11:06:33+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/glaukos-to-release-first-quarter-2023-financial-results-after-market-close-on-may-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/glaukos-to-release-first-quarter-2023-financial-results-after-market-close-on-may-3\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/glaukos-to-release-first-quarter-2023-financial-results-after-market-close-on-may-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55729","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55729"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55729\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55729"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55729"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}